MSD grabs Eyebiotech Ltd for US$1.3bn upfront
US pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.
ADVERTISEMENT
New Search
If you are not happy with the results below please do another search
56 search results for: MSD
Curve Therapeutics in US$1.7bn deal with MSD
/in Latest NewsCurve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
BIOncoTech Therapeutics and MSD combine cancer drugs
/in Latest NewsMadrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.
Noxxon/MSD start testing of immunoncologic combo
/in Latest NewsLast December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.
BerGenBio plans IPO and partners with MSD
/in Latest NewsNorwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.
Proteros inks US$167m oncology pact with MSD
/in Latest NewsProteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncology.
Super deal for BioNTech – BMS licenses potential blockbuster for €10bn
/in Latest NewsIn the race to replace MSD’s mega blockbuster pembrolizumab with a more effective bispecific VEGF x PD-(L)1 antibody, German company BioNTech SE has struck a good deal. BioNTech is now developing its Phase III programme BNT327, acquired with the US$950m takeover of Chinese company Biotheus Co Ltd, with Bristol Myers Squibb (BMS) in return for a payment of US$11.1bn.
Biotech Summit Austria 2025 in Graz
/inJoin the 3rd BIOTECH SUMMIT AUSTRIA on October 23–24, 2025, in Graz – the heart of Austria’s Medical Science City. This high-level conference connects biotech leaders, innovators, and investors to explore new trends, markets, and opportunities across Europe and beyond.
Reinforcement for Angelini Ventures
/in AppointmentsDr Regina Hodits joined Angelini Ventures, the VC arm of Angelini Industries, in April as the new Managing Director. She will be based in Germany and lead the company’s international biotech investment strategy with focus Biotech AI and therapeutics.
PHARMAP 2025: Collaborate with pharma leaders across the world
/in highlightPHARMAP 2025 brings together experts from all over the world in Berlin, Germany on 14-15 April to share how to make medicine smarter and safer. Leading pharmaceutical companies from the EU, Asia, North America, the Middle East, Africa and others participate in the Congress to find new contacts and expand their network.